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THE BURDEN OF DIABETIC NEPHROPATHY
By the year 2025, the World Heath Organization esti-
mates that over 300 million people worldwide will have
diabetes [1]. Over 5% of newly diagnosed patients with
type 2 diabetes will already have diabetic kidney disease
and a further 30% to 40% will develop diabetic nephropa-
thy, mostly within 10 years of diagnosis [2]. In patients
with type 1 diabetes, 25% to 40% will develop diabetic
nephropathy [3]. Although the proportion of patients
with type 1 diabetes developing nephropathy has reduced
markedly over the past 20 years in Western countries [4],
the increasing incidence and survival of patients with type
1 diabetes means that the absolute numbers of patients
with type 1 diabetes and diabetic nephropathy may con-
tinue to rise. By contrast, the incidence of both type 2
diabetes and diabetic nephropathy in these patients has
risen steadily over the last 50 years [3]. These facts, in com-
bination with the improved survival from cardiovascular
comorbidity, mean that diabetic nephropathy has now be-
come the single most common cause of end stage renal
disease (ESRD) in the Western world, with over half of
all patients on renal replacement programs now having
diabetes [5]. This figure significantly underestimates the
actual burden of diabetic renal disease, as the high mor-
tality rate from cardiovascular disease limits the full ex-
pression of diabetic nephropathy. Future improvements
in cardiovascular survival will see the natural history of
diabetic nephropathy played out in increasing numbers
of patients. This has already been seen in patients with
type 1 diabetes. For example, in 1971, the median survival
of patients with type 1 diabetes and overt nephropathy
was 5 years, with fewer than 10% surviving more than 10
years [6]. Consequently, few patients were able to stay the
course of their renal disease. By comparison, in 1996, the
median survival in an equivalent population was over 17
years [5]. Not surprisingly, nearly ten times more patients
with type 1 diabetes are now entering ESRD programs.
In this context, this article reviews both basic and clinical
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research, aimed at slowing the accrual of diabetic patients
with renal disease.
GLYCEMIC CONTROL
Current management practices are based around the
assumption that the best way to reduce the risk for mi-
crovascular complications is to achieve optimal glycemic
control. This is based on the paradigm that hyperglycemia
is necessary for the initiation of renal injury, as pa-
tients without diabetes do not develop diabetic nephropa-
thy. However, patients receiving intensive therapy de-
signed to achieve excellent glycemic control, still develop
nephropathy and progress to ESRD, albeit at a slower
rate [7]. While glycemic control is undoubtedly a valuable
and important treatment, exogenous insulin therapy or
oral hypoglycemics cannot match the kinetics of a healthy
endocrine system. It seems likely that, short of islet cell
transplantation/regeneration, at best occasional hyper-
glycemia is unavoidable in patients with diabetes. Fur-
thermore, it is clear that continuous florid hyperglycemia
is not necessarily required for diabetic hyperfiltration
and renal hypertrophy to occur. Indeed, these changes
may persist in patients with type 1 diabetes even after
euglycemia is achieved through aggressive insulin ther-
apy [8]. It may be that intermittent signals in the form
of transient elevations in filtered glucose are sufficient
to stimulate kidney growth and contribute to sustained
glomerular hyperfiltration. That relatively minor levels of
dysglycemia may be sufficient to initiate renal disease is
further supported by the finding that renal structural fea-
tures, characteristic of diabetic nephropathy, may be ob-
served in both animals and patients with impaired glucose
tolerance before the appearance of overt diabetes [9]. In
addition, albuminuria is correlated with glucose levels in
the nondiagnostic range in patients without diabetes or
hypertension [10]. With this in mind, it is conceivable that
many cases of so-called “nondiabetic albuminuria” re-
flect the smoothing function of hemoglobin A1c (HbA1c)
in masking transient elevations in plasma glucose, and
inadequacies in current diagnostic procedures in identify-
ing patients with occult dysglycemia. Ultimately, if hyper-
glycemia cannot be effectively prevented, the only way
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to prevent nephropathy in patients with diabetes will be
to disrupt the pathways that lead from hyperglycemia to
injury.
HYPERTENSION
The rate of progression of diabetic renal disease is
closely correlated with the blood pressure at baseline,
perhaps more so than with metabolic control. Indeed,
in patients with baseline hypertension, glycemic control
may have little independent predictive value [11]. Clearly,
neither hemodynamic nor metabolic pathways act inde-
pendently in patients with diabetes. It is likely these path-
ways interact in the genesis and progression of diabetic
renal lesions. However, a sustained reduction in blood
pressure appears to be currently the most important sin-
gle intervention to slow progressive diabetic nephropathy
in both type 1 and type 2 diabetes. For example, in the
United Kingdom Diabetes Prospective Study (UKDPS)
study a reduction of blood pressure from 154 to 144 mm
Hg was associated with a 30% reduction in microalbu-
minuria [12].
Current international guidelines suggest a blood pres-
sure target of 130/80 mm Hg for diabetic patients, and
in the presence of proteinuria and/or renal impairment
an even lower blood pressure goal of 125/75 mm Hg. To
achieve these levels, particularly in patients with estab-
lished diabetic nephropathy, most patients will require
three to four different antihypertensive agents. In the
end, blood pressure control, however it is achieved, is as-
sociated with renoprotective effects, although there may
be particular advantages conferred following blockade of
the renin-angiotensin system (RAS).
RAS
Activation of the intrarenal RAS and the subsequent
generation of angiotensin II (Ang II) appear to be among
the most important mediators of hemodynamic changes
in diabetic nephropathy. This is illustrated by the accel-
erated progression of diabetic nephropathy associated
with genetic overactivity of the RAS in the Ren-2 rat
[13] and in patients homozygous for the D allele of the
angiotensin-converting enzyme (ACE) gene [14]. In ad-
dition, renal protection has been clearly demonstrated in
both type 1 and type 2 diabetic patients, following block-
ade of the RAS with ACE inhibitors or angiotensin type
1 (AT1) receptor antagonists [15–17]. In a meta-analysis
of 12 trials, including microalbuminuric, nonhypertensive
patients with type 1 diabetes, the risk of progression to
macroalbuminuria was reduced by 60% following ACE
inhibition and the chance of regression to normoalbu-
minuria significantly increased [18]. For the AT1 recep-
tor antagonists, it has clearly been demonstrated in type
2 diabetic patients with proteinuria [16, 19] and with
microalbuminuria [20] that this class of agents reduce
progression to ESRD in association with a reduction in
proteinuria. In these trials, blockade of the RAS appears
to confer superior renoprotection compared to conven-
tional or calcium channel blocker–based therapies. Al-
though long-term large-scale studies directly comparing
ACE inhibitor versus angiotensin receptor blocker treat-
ment in diabetic nephropathy are missing, there is ev-
idence that both agents confer similar renoprotective
effects in diabetic nephropathy [17]. Combination ther-
apies, including both an ACE inhibitor and AT1 recep-
tor antagonists, have been increasingly investigated and
shown to have additive and possibly synergistic effects on
blood pressure and proteinuria [21, 22].
While blood pressure reduction is a key component of
these therapies, the effects of locally produced Ang II
in diabetes are not limited to the hemodynamic actions
of this peptide. Ang II is also an important stimulus for
tubular hypertrophy with the induction of growth factors,
including transforming growth factor beta (TGF-b1) and
epidermal growth factor (EGF). The potential source of
the intrarenal RAS activation in diabetes remains to be
established. Patients with poor glycemic control have a
greater reduction in intrarenal vascular resistance, fol-
lowing blockade of the RAS, than patients with good
control [23], consistent with the hypothesis that activity of
the intrarenal RAS may be influenced by glucose. How-
ever, factors beyond plasma glucose levels contribute to
this RAS activation, as euglycemia does not normalize
the response to AT1 receptor blockade in patients with
diabetes [24].
DYSLIPIDEMIA
Dyslipidemia is an important risk factor for the de-
velopment and progression of diabetic kidney disease.
In the apolipoprotein E knockout model associated with
marked hyperlipidemia, induction of diabetes results in
accelerated nephropathy with significant renal injury de-
tectable by 20 weeks of disease (Fig. 1) [25]. Similar find-
ings have been observed in clinical studies. For example,
Krolewski, Warram, and Christlieb [26] demonstrated a
more rapid loss of renal function in proteinuric patients
associated with elevated serum cholesterol levels. Sim-
ilarly, in the World Health Organization multinational
study of vascular disease in patients with microalbumin-
uria, elevated serum triglycerides were associated with
an increased risk of progression to renal failure [27]. As
dyslipidaemia may also be a consequence of renal dis-
ease and, in particular, proteinuria, interpretation of lipid
levels in the context of nephropathy may be problem-
atic. Although animals studies have suggested that lipid
lowering may positively impact on the progression of re-
nal disease in experimental diabetes [28], intervention
studies in patients with type 1 diabetes have been less
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Fig. 1. Glomerular hypertrophy and mesan-
gial expansion in diabetic c57 and diabetic
apolipoprotein E knockout mice. (A) c57. (B)
Diabetic c57. (C) Apolipoprotein E knock-
out control. (D) Diabetic apolipoprotein E
knockout [periodic acid-Schiff (PAS) staining
×400].
convincing, with only one small randomized controlled
trial showing only a modest effect on albuminuria [29].
Findings in type 2 diabetes are more persuasive, with
the Heart Protection Study demonstrating that simvas-
tatin significantly reduced the fall in glomerular filtration
rate (GFR) in high-risk patients with and without type
2 diabetes [30]. Large prospective studies evaluating the
renoprotective effects of antilipidemic treatments and in
particular statins are now needed to examine the role of
lipid-based intervention in slowing progressive diabetic
nephropathy.
ADVANCED GLYCATION
Prolonged hyperglycemia, dyslipidemia, and oxidative
stress in diabetes result in the formation and accumula-
tion of advanced glycation end products (AGEs) in the
kidney, in atherosclerotic plaques and at other sites of dia-
betic complications [31]. AGEs have been shown to have
a wide range of chemical, cellular, and tissue effects that
potentially could contribute to progressive nephropathy.
Their importance as downstream mediators of hyper-
glycemia in diabetes has been amply demonstrated in
animal studies using inhibitors of advanced glycation to
retard the development of diabetic nephropathy without
directly influencing plasma glucose levels [32]. Further-
more, direct in vivo exposure to AGEs is able to generate
lesions similar to those seen in diabetic nephropathy [33].
AGE modification leads to changes in charge, solubil-
ity, and conformation, ultimately resulting in molecular
dysfunction. AGEs also interact with specific receptors
and binding proteins to influence the renal expression
of growth factors and cytokines, implicated in the pro-
gression of diabetic renal disease. The effects of AGEs
appear to be synergistic with other pathogenic pathways
in diabetic nephropathy. Most notably, oxidative stress,
hypertension, and activation of the RAS play a key role
in determining the actions of AGEs [34], as well as pro-
moting AGE formation in their own right in a vicious cy-
cle associated with progressive renal damage. It is likely
that therapies that inhibit the formation of AGEs or
remove established AGE modifications will form an im-
portant component of future therapy in patients with di-
abetes, acting in concert with conventional approaches to
prevent diabetic renal injury. At present, the efficacy of
inhibitors of renal AGE accumulation remains to be
established in large clinical trials. Notably, large clini-
cal studies of pimagedine (aminoguanidine) in patients
with type 1 diabetes (ACTION 1) and type 2 diabetes
(ACTION 2) and overt nephropathy were terminated,
due to safety concerns and apparent lack of efficacy.
Nonetheless, pimagedine was associated with a reduc-
tion in urine protein excretion in a subpopulation of
patients with moderate renal impairment [35]. Smaller
studies with aminoguanidine have demonstrated signif-
icant improvements in red cell deformability and dys-
lipidemia [36]. Clinical studies with the novel “cross-link
breaker,” Alagebrium chloride, in patients with diabetes
are keenly awaited.
ANEMIA
Anemia is a common finding in diabetes, particularly
in patients with overt nephropathy or renal impairment.
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Fig. 2. The prevalence of functional erythropoietin (EPO) deficiency
(<31 IU/mL) and reduced iron availability [transferrin saturation
(TSAT) <16%] in patients with type 2 diabetes and anemia, stratified
according to the renal function. GFR is glomerular filtration rate.
We have recently shown that at least one in five outpa-
tients with type 1 or type 2 diabetes in tertiary clinics have
anemia. Furthermore, anemia in patients with diabetes is
associated with an increased risk of diabetic complica-
tions, including nephropathy, retinopathy, and macrovas-
cular disease [37]. Reduced hemoglobin levels, even
within the normal range, identify patients with type 2
diabetes at increased risk for progressive renal disease,
hospitalization, and premature death [16]. It is important
to note that anemia itself does not cause microvascular
injury. Moreover, as anemia may be considered a man-
ifestation of microvascular disease, it is easy to see how
patients with anemia may appear more susceptible to ag-
gressive renal disease. Nevertheless, there is some evi-
dence to suggest that anemia has an independent effect
on the progression of diabetic nephropathy. For example,
in patients with diabetes at our center, the prevalence of
vascular complications was significantly increased in pa-
tients with anemia, regardless of etiology and whether
or not erythropoietin (EPO) levels were appropriately
elevated (Fig. 2). This finding suggests that anemia per
se is an independent risk factor for progressive renal
disease.
There now have been three prospective clinical stud-
ies in patients with advanced nephropathy to show de-
layed deterioration of renal function in patients in whom
anemia was corrected with exogenous EPO [38–40]. It
is notable that these studies were in patients with ad-
vanced renal disease rather than specifically diabetic
nephropathy. The potential utility of correction of ane-
mia in patients with early renal injury and specifically
in patients with diabetes has not been formally tested.
It is hoped that upcoming trials involving the correction
of anemia in patients with diabetes will help clarify the
optimal approach to this disorder [41]. In the interim,
the detection of anemia should be used to identify pa-
tients with diabetes at increased risk of adverse clinical
outcomes.
PROTEIN RESTRICTION
Low protein diets have been recommended as a treat-
ment for reducing proteinuria and retarding progres-
sion of chronic renal disease since the 1930s. However,
clear evidence for its efficacy in patients with diabetic
nephropathy is lacking. A small body of evidence suggests
that patients with type 1 diabetes and overt nephropa-
thy should restrict protein intake to 0.75g/kg/day (the
World Health Organization recommended minimum safe
daily intake). In a meta-analysis of five trials, Waugh and
Robertson [42] found that protein restriction was effec-
tive in reducing renal failure or death. However, in pa-
tients with type 2 diabetes, there are minimal data for
low protein diet showing reduced progression in patients
with with overt nephropathy. The expected benefits that
can be achieved through protein restriction in patients
with diabetic nephropathy are at best modest in compar-
ison with adequate blood pressure control and blockade
of the RAS. Moreover, the nutritional impact of such in-
terventions must be carefully considered, particularly in
patients with brittle glycemic control.
ANTIOXIDANTS
Oxidative stress has a critical role in the pathogenesis
of diabetic nephropathy. There are a number of sources
for the formation of reactive oxygen species in diabetes,
including the auto-oxidation of glucose, lipid peroxida-
tion, AGEs, mitochondrial respiratory chain deficien-
cies, xanthine oxidase activity, peroxidases, nitric oxide
synthase (NOS), and nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (Nox) to name but a few.
Our own studies have demonstrated an increased expres-
sion of the membrane-bound nox-4 subunit within the
kidney in experimental diabetes [43]. In addition, en-
dogenous antioxidant activity may be impaired in pa-
tients with diabetes, and these derangements are of a
higher magnitude in patients with nephropathy. Consis-
tent with the role of oxidative stress in diabetic nephropa-
thy, a number of experimental studies have shown that
antioxidants such as vitamin E and probucol retard the
progression of renal disease in experimental diabetes.
However, long-term vitamin E supplementation in pa-
tients with diabetes and vascular disease had no effect on
microvascular outcomes, including nephropathy. More-
over, results from the HOPE and HOPE TOO Studies
give some cause for concern. Indeed, in patients with dia-
betes mellitus, long-term vitamin E supplementation may
increase the risk of heart failure [44]. In addition, a re-
cent meta-analysis reported increased mortality in trials
using high-dose vitamin E (>400 IU/day). It is possible
that a-tocopherol may become a pro-oxidant in an oxida-
tive milieu, or that supplementation may alter the natural
balance of endogenous antioxidant systems. While it is
conceivable that other, more targeted, antioxidants may
Cooper et al: Targets to retard progression of diabetic nephropathy 1443
have some clinical benefit, the validity of this hypothe-
sis remains to be established by appropriately designed
clinical trials.
FIBROGENESIS
Glomerular and interstitial fibroses are key compo-
nents of diabetic nephropathy, that best correlate with
progressive renal disease. Consequently, targeted inter-
vention to disrupt progressive fibrogenesis in the diabetic
kidney has been seen as a potentially valuable adjunct
to conventional interventions. A number of prosclerotic
cytokines such as TGF-b and connective tissue growth
factor (CTGF) have been postulated to be excellent
targets for developing antifibrotic therapies in diabetic
nephropathy [45]. However, at this stage the lack of orally
available molecules to inhibit these pathways has ham-
pered progress in this area. Our own group has recently
tested the drug imatinib, which is used for treatment of
chronic myeloid leukemia. This tyrosine kinase inhibitor
attenuates platelet-derived growth factor (PDGF) recep-
tor phosphorylation with recent studies demonstrating in
a murine model of accelerated diabetic nephropathy re-
duced renal injury in association with reduced fibrosis
[46]. As the profibrotic pathways for renal disease are
increasingly elucidated, it is likely that current and new
molecules will become available as effective antifibrotic
therapies in disorders such as diabetic nephropathy.
ALBUMINURIA AS A TARGET
FOR INTERVENTION
Microalbuminuria is a biomarker of microvascular dis-
ease, the worse the disease the greater the amount of
albuminuria. While the presence of diabetic nephropa-
thy represents a marker for poor vascular outcome in
diabetes, the onset of microalbuminuria does not irrevo-
cably seal the fate of the patient. Spontaneous regres-
sion to normoalbuminuria may be observed in a sizeable
proportion of patients with both type 1 and type 2 di-
abetes. Whether this represents recovery of glomerular
integrity, as demonstrated after isolated pancreas trans-
plantation [47], remains to be established. In addition,
it remains to be determined if remission of microalbu-
minuria can be sustained. However, this does not in any
way diminish the importance of reducing albuminuria in
diabetic nephropathy. Data from the RENAAL Study
suggest that any reduction in albuminuria following inter-
vention is associated with a proportional effect on renal
protection [48]. Moreover, the degree of residual albu-
minuria after treatment is also linearly correlated with
renal risk. Importantly, the relationship between risk and
albuminuria in treated patients is similar to that observed
between renal risk and baseline albuminuria (i.e., in the
RENAAL Study, 2 g of albuminuria in a patient NOT
taking losartan carried the same risk as 2 g albuminuria
in a patient receiving losartan). Reducing residual albu-
minuria to its lowest achievable level should be a key goal
for all renoprotective treatment in diabetes.
THE FUTURE OF PROGRESSIVE
NEPHROPATHY
Although hypertension, glycemic control and base-
line albuminuria certainly contribute to progression, it
is important to note that these variables explain less that
one third of the variation in rates of progression among
patients. There remain patients who, despite prolonged
hyperglycemia and poor blood pressure control, ap-
pear resistant to the development of diabetic renal dis-
ease. Similarly, there are patients who, despite optimal
glycemic control, seem to spiral inexorably toward renal
failure and a premature death. It is not currently possible
to predict which patients will develop diabetic nephropa-
thy. Thus, there remains an urgent need for new targets
and new interventions to stem the inexorable tide of dia-
betic renal disease.
That does not mean that nothing can be done. There
is clear evidence that renal disease in type 1 diabetes is
on the decline, partly as a result of improved blood pres-
sure management. Moreover, a multifactorial approach,
such that used by the STENO 2 Study, may be even more
effective in preventing progressive nephropathy [49].
However, such strategies are difficult to apply without
adequate resources and a significant commitment on the
part of both patient and physician. It seems likely that
the interaction of metabolic and hemodynamic factors
compounds the deleterious effects of the diabetic milieu
and reduces the threshold for injury via common mech-
anisms. Therapies that target multiple pathways may in-
deed be more successful than those that target one alone.
Nevertheless, it remains to be determined if a strat-
egy addressing the combination of hemodynamic and
metabolic pathways will be more effective than any in-
dividual therapy in preventing diabetic nephropathy in
the clinical context. Certainly, experimental studies sug-
gest that combination approaches may be superior, with
our group demonstrating that blockade of the RAS and
inhibition of advanced glycation have synergistic effects
toward the prevention of diabetic nephropathy [50]. In-
deed, combination therapy proved more effective in pre-
venting glomerulosclerosis and tubulointerstitial damage
than standard monotherapies, with superior reductions in
albuminuria.
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